Decay-Accelerating Factor Expression Modulates the Severity of Experimental Focal Segmental Glomerulosclerosis. Issue 3 (March 2023)

• Record Type: Journal Article
• Authors: Bin, Sofia; Budge, Kelly; Gentile, Micaela; Podestà, Manuel Alfredo; Khan, Yaseen; Azzi, Jamil R.; Sanchez Russo, Luis; La Manna, Gaetano; Cravedi, Paolo
• Is Part Of: Kidney360. Volume 4:Issue 3(2023)
• Page Start: 381
• Page End: 386
• Publication Date: 2023-03
• Subjects: glomerular and tubulointerstitial diseases -- adriamycin -- basic science -- C3 -- C3aR -- CD55 antigens -- complement -- DAF -- focal segmental glomerulosclerosis; 616.61
• DOI: 10.34067/KID.0005312022
• Languages: English
• ISSNs: 2641-7650

Abstract

Abstract : Key Points: Genetically induced decay-accelerating factor (DAF) overexpression prevents adriamycin (ADR)-induced focal segmental glomerulosclerosis (FSGS) in mice. Pharmacologic inhibition of DAF cleavage reduces complement activation in the glomeruli and albuminuria in murine ADR-induced FSGS. Inhibition of complement activation represents a valuable therapeutic strategy for FSGS and, potentially, other glomerular diseases.